Is longevity science stuck? Researchers call for a strategic reset

• Have we been targeting aging the wrong way?
• Is lifespan extension the wrong objective?
• Could resilience — not longevity — be the true therapeutic endpoint?

These questions will frame the International Conference on Targeting Longevity 2026 (April 8–9, Berlin), where scientists and industry leaders will examine whether aging should be redefined as a systems-level failure rather than a collection of molecular defects.

Speakers including:
Nancy M. Bonini, Yuji Naito, João Pedro de Magalhães, Yasukazu Nakamura, William Lowry, Viktor Korolchuk, João F. Passos, and Tohru Minamino will discuss emerging evidence suggesting that aging reflects loss of coordination between mitochondria, microbiota, immune signaling, and metabolic regulation.

This perspective challenges dominant models focused on individual pathways such as senescence, mTOR signaling, or metabolic targets. While these approaches have produced important insights, their clinical translation has remained limited.

Some researchers now speculate that longevity interventions may require coordinated modulation of biological networks rather than single target therapies. Others propose that future strategies may resemble resilience engineering, stabilizing biological systems rather than attempting to reverse aging directly.

Industry interest reflects this shift. Companies attending include Nadmed, Amoeba, Arterra Bioscience SpA, Beiersdorf AG, Blue Oak Nx, Corus, Dr Irena Eris S.A., EpiGenEdit, Frisch GmbH Forever Beautiful, IMD Berlin, Hermès, Industrias Asociadas SL, L’Occitane en Provence, L’OREAL, Mibelle Biochemistry, MK Medical Aesthetic, Natura, Pierre Fabre, Rubisco Biotechnology, Springer Nature, Synbalance Srl, and Synlab Mvz Leinfelden. 

“Longevity research has produced extraordinary discoveries, yet implementation remains fragmented,” said Dr. Marvin Edeas, organizer and chairman of the scientific board. “We may need to rethink aging as a loss of biological coordination. The next phase of longevity science will likely focus on restoring resilience across interconnected systems.”

The Berlin meeting aims to explore whether this conceptual shift could redefine research priorities, therapeutic development, and business models in the rapidly growing longevity sector.

If aging is not a single process but a network failure, the future of longevity may depend on learning how to stabilize biological complexity rather than simply extending lifespan.

About Targeting Longevity 2026

Targeting Longevity 2026 explores whether longevity science requires a strategic reset. The meeting examines aging as a systems level loss of coordination involving mitochondria, microbiota, immunity, and metabolism. By focusing on resilience rather than single pathways, the conference aims to identify new translational strategies and industrial opportunities.

For more information about the congress & agenda: https://targeting-longevity.com/